For me personally, this is disappointing on several levels: • As a scientist, because it limits the opportunity to test treatments that could potentially help patients. • As a representative of the broader field of Post-Acute Infection Syndromes (PAIS), because excluding the most promising candidates raises questions about how effectively the available €3.5 million is going to be spent. • And also on a personal level, as a family member of an ME/CFS patient, because this means that a major opportunity to test promising treatments for ME/CFS in the Netherlands may not materialize in the foreseeable future. I would like to sincerely thank everyone involved in preparing for this call (both scientists and patients) who invested enormous effort in reviewing biomedical literature, discussing possible treatments, and providing feedback from the patient community. That work will not be in vain. Progress in ME/CFS research has always required persistence. This moment is disappointing, but we will continue our search for effective treatments, one way or another. More information about the call: https://lnkd.in/e2eqxpAp Promising medicines for ME/CFS: call for drug repurposing
3/
Disappointing information about ME/CFS treatment trial fund in the Netherlands
#CVS #MECVS #MEcfs #CFS #PwME #MyalgicEncephalomyelitis #ChronicFatigueSyndrome
www.linkedin.com/posts/jdendu... @drdendunnen.bsky.social
